Roche Signs US$2.8 B Deal with Alnylam to Develop RNAi Therapeutic for Hypertension
By Amit Kaushik
Pharma Deals Review: Vol 2023 Issue 8 (Table of Contents)
Published: 2 Aug-2023
DOI: 10.3833/pdr.v2023.i8.2798 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a groundbreaking move with the potential to revolutionise the treatment of cardiovascular diseases, Roche has entered into a licensing agreement with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS